Clinical trials
Acute Myeloid Leukemia, in Relapse clinical trials
Below are recruiting acute myeloid leukemia, in relapse clinical trials, each written for real people, not researchers. We’re tracking 284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05659732RecruitingPhase 1
Testing a new drug for advanced blood cancers
This early-phase study tests PEP07, a drug that blocks a cancer signal pathway (Checkpoint Kinase 1). It aims to see how well it works and how safely it can be given to people with certain advanced relapsed or refractory blood cancers.
Clayton, VictoriaAges 18 years+ - NCT05904106RecruitingPhase 2
Venetoclax plus azacitidine versus stronger chemotherapy for AML
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
Essen, North Rhine-WestphaliaAges 18–70 - NCT05909293Recruiting
Venetoclax maintenance for older adults with AML in remission
This study tests whether “maintenance” treatment with venetoclax can help older adults with acute myeloid leukemia (AML) stay in remission after initial therapy. It may help delay the return of AML, especially in people who achieved first complete remission.
Nanjing, JiangsuAges 60–85 - NCT05986240RecruitingPhase 1
Danvatirsen with or without venetoclax for advanced MDS or AML
This trial tests a new drug called danvatirsen, first alone and then combined with venetoclax, for people with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if this approach can help when other options have stopped working.
The Bronx, New YorkAges 18 years+ - NCT06191263RecruitingPhase 2
RVU120 plus venetoclax for relapsed AML
This trial tests a new drug, RVU120, combined with venetoclax for people with AML that has come back or not responded to treatment. It may be an option if you've already tried venetoclax with another drug and it didn't work.
GrenobleAges 18 years+ - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06424340RecruitingPhase 1/Phase 2
Cell therapy for relapsed or refractory AML with NPM1 mutation
This trial tests a new type of cell therapy, called MB-dNPM1-TCR.1, for people with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The therapy uses your own immune cells, which are specially trained to find and attack leukemia cells that have a specific mutation in the NPM1 gene.
LeidenAges 18 years+ - NCT06458244Recruiting
Stem cell transplant for high-risk CBF-AML
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT05945849RecruitingPhase 1
Modified stem cells and CAR T cells for hard-to-treat AML
This trial tests a new approach for people with acute myeloid leukemia (AML) that has not gotten better with standard treatments. First, you receive modified stem cells, then specially designed immune cells (CAR T cells) that target a protein called CD33 on leukemia cells. The goal is to see if this combination can safely help your body fight the leukemia.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06550713RecruitingPhase 1
Testing TQB3455 tablets for blood cancers with IDH2 mutation
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06690827RecruitingPhase 1
Cd123-targeted car-nk cells for relapsed aml or bpdcn
This trial tests a new treatment using your own immune cells (natural killer cells) that are modified to find and attack cancer cells with a marker called CD123. It is for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard therapies.
Wuhan, HubeiAges 18–75 - NCT06707493RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
Atlanta, GeorgiaAges 18–75 - NCT06714591RecruitingPhase 1
Testing BL-M11D1 for advanced AML
This trial tests a new drug called BL-M11D1 for people with a type of leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and works against cancer cells that have a protein called CD33.
Duarte, CaliforniaAges 18 years+ - NCT06786533RecruitingPhase 1
CAR-T cells for hard-to-treat AML
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
Houston, TexasAges 12 years+ - NCT07075016RecruitingPhase 3
IDH1 mutation targeted therapy for untreated AML
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
FeldkirchAges 18 years+ - NCT07132684RecruitingPhase 3
Comparing two chemotherapy plans for older AML patients
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
TianjinAges 55–75 - NCT07270978RecruitingPhase 1
CD33-targeting cells for leukemia with leftover cancer cells
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
Charlottesville, VirginiaAges 18 years+ - NCT02203903RecruitingPhase 1
Donor T-cell treatment after transplant for high-risk AML and MDS
This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.
Washington D.C., District of ColumbiaAges 6 months–80 years - NCT02781883RecruitingPhase 2
Test drug BP1001 with venetoclax and decitabine for AML
This Phase 2 study tests BP1001 added to venetoclax plus decitabine in adults with acute myeloid leukemia (AML). It aims to improve leukemia control in people who may not be able to get standard intensive chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT07532824RecruitingPhase 1/Phase 2
Proton Radiation and Stem Cell Transplant for High-Risk Blood Cancers
This trial tests a new type of radiation therapy (proton-based) combined with a stem cell transplant from a donor to treat advanced forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to improve survival in patients with aggressive or hard-to-treat disease.
PragueAges 18–65 - NCT07588360Recruiting
Stem cell transplant for acute myeloid leukemia or myelodysplastic syndrome
This trial tests a type of stem cell transplant (using cells from a partially matched donor and umbilical cord blood) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to help patients whose disease is high-risk, has returned after treatment, or hasn't responded well to chemotherapy.
Fuzhou, FujianAges 14–60 - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Birmingham, AlabamaAges 18 years+ - NCT06523556RecruitingPhase 1/Phase 2
Axatilimab with or without azacitidine for advanced blood cancers
This trial tests a new drug, axatilimab, given alone or with another drug (azacitidine) for people with advanced forms of blood cancers like certain leukemias and myelofibrosis. It may help if your disease has not responded to earlier treatments or if you are starting treatment for the first time.
Columbus, OhioAges 18 years+ - NCT06686108RecruitingPhase 2
Medication combo to prevent lymphoma relapse after transplant
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
ShanghaiAges 14–55
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute myeloid leukemia, in relapse?
- Yes. Clin2 currently lists 284 recruiting acute myeloid leukemia, in relapse studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute myeloid leukemia, in relapse trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute myeloid leukemia, in relapse trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.